- Home
- IRD vs COCH Comparison
IRD vs COCH Comparison
Compare IRD & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- COCH
- Stock Information
- Founded
- IRD 2018
- COCH 1995
- Country
- IRD United States
- COCH United States
- Employees
- IRD N/A
- COCH N/A
- Industry
- IRD
- COCH Blank Checks
- Sector
- IRD
- COCH Finance
- Exchange
- IRD NYSE
- COCH Nasdaq
- Market Cap
- IRD 36.1M
- COCH 29.8M
- IPO Year
- IRD N/A
- COCH N/A
- Fundamental
- Price
- IRD $1.13
- COCH $1.61
- Analyst Decision
- IRD Strong Buy
- COCH Strong Buy
- Analyst Count
- IRD 1
- COCH 3
- Target Price
- IRD $8.00
- COCH $8.00
- AVG Volume (30 Days)
- IRD 159.2K
- COCH 33.0K
- Earning Date
- IRD 02-15-2025
- COCH 11-14-2024
- Dividend Yield
- IRD N/A
- COCH N/A
- EPS Growth
- IRD N/A
- COCH N/A
- EPS
- IRD N/A
- COCH N/A
- Revenue
- IRD $8,381,000.00
- COCH $278,000.00
- Revenue This Year
- IRD N/A
- COCH N/A
- Revenue Next Year
- IRD $29.37
- COCH $19.76
- P/E Ratio
- IRD N/A
- COCH N/A
- Revenue Growth
- IRD N/A
- COCH 15.35
- 52 Week Low
- IRD $0.81
- COCH $1.14
- 52 Week High
- IRD $2.77
- COCH $11.46
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- COCH 52.87
- Support Level
- IRD N/A
- COCH $1.25
- Resistance Level
- IRD N/A
- COCH $1.61
- Average True Range (ATR)
- IRD 0.00
- COCH 0.14
- MACD
- IRD 0.00
- COCH 0.04
- Stochastic Oscillator
- IRD 0.00
- COCH 97.87
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.